Verseon's drug discovery platform is applicable to any clinical target with a known protein structure and, as such, provides the company with great program flexibility.

Current pipeline

Verseon has used its drug discovery platform to build its drug portfolio comprising different therapeutic areas.

Discovery Preclinical Phase 1 Phase 2 Phase 3
Diabetic Macular Edema
Hereditary Angioedema
Metabolic Disorders

Future programs

Verseon is actively evaluating targets for future development. Selection is based on careful planning and involves several criteria including:

  1. Unmet market need
  2. Available target structure
  3. Favorable preclinical and clinical endpoints

Our current drug portfolio spans four separate therapeutic areas, all with unmet (or poorly met) medical needs


Current Pipeline

First-in-class oral anticoagulants for cardiovascular indications

Kallikrein inhibitors for the treatment of diabetic macular edema

Kallikrein inhibitors for the treatment of hereditary angioedema

Novel angiogenesis inhibitors for the treatment of solid tumors